ENG/中
老虎证券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登录
立即注册
Toggle
美股
详情
本页面由Tiger Trade Technology Pte. Ltd.提供服务
Virtus LifeSci Biotech Products ETF
96.92
-1.2719
-1.30%
盘后:
96.92
0.0000
0.00%
16:10 EDT
成交量:
5,451
成交额:
52.99万
市值:
9,692.47万
市盈率:
- -
高:
98.05
开:
97.84
低:
96.61
收:
98.20
52周最高:
105.21
52周最低:
60.91
股本:
100.00万
流通股本:
100.00万
量比:
0.51
换手率:
0.55%
股息:
- -
股息率:
- -
净资产收益率:
--
总资产收益率:
--
市净率:
--
市盈率(LYR):
- -
数据加载中...
总览
公司
新闻
公告
概念
没有相关数据
资金流向
资金流入:
资金流出:
实时
日
周
月
季度
年
新闻
免疫疾病生物制药公司Attovia(ATTO.US)申请在美上市 拟募资1亿美元
中金财经
·
07/15
免疫疾病生物制药公司Attovia(ATTO.US)申请在美上市 拟募资1亿美元
智通财经
·
07/15
免疫疾病生物制药公司Attovia(ATTO.US)申请在美上市 拟募资1亿美元
智通财经
·
07/15
英硅智能早盘涨超7% 与康哲药业达成AI+创新药研发新合作
新浪港股
·
07/13
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BBP"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BBP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBP\",,,,,undefined,":{"symbol":"BBP","market":"US","secType":"STK","nameCN":"Virtus LifeSci Biotech Products ETF","latestPrice":96.9243,"timestamp":1784232000000,"preClose":98.1962,"halted":0,"volume":5451,"hourTrading":{"tag":"盘后","latestPrice":96.9243,"preClose":96.9243,"latestTime":"16:10 EDT","volume":9,"amount":872.3187,"timestamp":1784232604633,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.012952639715182483,"floatShares":1000004,"shares":1000004,"eps":0,"marketStatus":"盘后交易","change":-1.2719,"latestTime":"07-16 19:06:59 EDT","open":97.84,"high":98.045,"low":96.61,"amount":529934,"amplitude":0.014614,"askPrice":145.14,"askSize":200,"bidPrice":87,"bidSize":2,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1784246400000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":98.1962,"sharesOutstanding":600004,"nav":97.286,"aum":97286720.5,"bidAskSpread":0.002515,"postHourTrading":{"tag":"盘后","latestPrice":96.9243,"preClose":96.9243,"latestTime":"16:10 EDT","volume":9,"amount":872.3187,"timestamp":1784232604633,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.513287,"impliedVol":0.2607,"impliedVolPercentile":0.8526},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBP\",,,,,undefined,":{"symbol":"BBP","floatShares":1000004,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.513287,"shares":1000004,"dividePrice":0,"high":98.045,"amplitude":0.014614,"preClose":98.1962,"low":96.61,"week52Low":60.91,"pbRate":"--","week52High":105.21,"institutionHeld":0,"latestPrice":96.9243,"committee":-0.980198,"eps":0,"divideRate":0,"volume":5451,"delay":0,"ttmEps":0,"open":97.84,"prevYearClose":79.9149,"prevWeekClose":100.26,"prevMonthClose":96.2686,"prevQuarterClose":96.2686,"fiveDayClose":103.6198,"twentyDayClose":87.5667,"sixtyDayClose":87.2315},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBP\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBP\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBP\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2651774435","title":"免疫疾病生物制药公司Attovia(ATTO.US)申请在美上市 拟募资1亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2651774435","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651774435?lang=zh_cn&edition=fundamental","pubTime":"2026-07-15 11:17","pubTimestamp":1784085422,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,临床阶段生物制药公司Attovia Therapeutics已提交首次公开募股申请,计划募集最多1亿美元资金。该公司计划在纳斯达克上市,股票代码为“ATTO”。 据悉,Attovia利用其ATTOBODY平台开发用于治疗免疫介导性疾病的生物制剂。Alamar于2023年设立Attovia作为独立公司,以便自身专注于蛋白质组学和疾病检测业务,目前仍是Attovia的重要股东。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260715/32307966.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["IBBQ","IPOS","MRNX","BBP","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651435511","title":"免疫疾病生物制药公司Attovia(ATTO.US)申请在美上市 拟募资1亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2651435511","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651435511?lang=zh_cn&edition=fundamental","pubTime":"2026-07-15 10:45","pubTimestamp":1784083531,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,临床阶段生物制药公司Attovia Therapeutics已提交首次公开募股申请,计划募集最多1亿美元资金。据悉,Attovia利用其ATTOBODY平台开发用于治疗免疫介导性疾病的生物制剂。自通过IPO融资2.2亿美元以来,Alamar股价已上涨近60%。Alamar于2023年设立Attovia作为独立公司,以便自身专注于蛋白质组学和疾病检测业务,目前仍是Attovia的重要股东。Attovia的核心候选药物ATTO-1310针对白细胞介素-31,目前已完成针对健康志愿者以及患有慢性瘙痒症和特应性皮炎患者的Ⅰ期临床试验给药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467668.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","BBP","MRNY","IBBQ","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651435505","title":"免疫疾病生物制药公司Attovia(ATTO.US)申请在美上市 拟募资1亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2651435505","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651435505?lang=zh_cn&edition=fundamental","pubTime":"2026-07-15 10:45","pubTimestamp":1784083531,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MRNX","MRNY","BBP","IBBQ","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651162210","title":"英硅智能早盘涨超7% 与康哲药业达成AI+创新药研发新合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2651162210","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651162210?lang=zh_cn&edition=fundamental","pubTime":"2026-07-13 10:02","pubTimestamp":1783908120,"startTime":"0","endTime":"0","summary":" 英硅智能早盘涨超7%,截至发稿,股价上涨6.21%,报45.48港元,成交额3.32亿港元。 7月13日,据英硅智能官微消息,公司宣布与康哲药业在中枢神经系统领域开展另一项AI驱动的药物发现合作。 根据合作协议,双方将结合英硅智能已验证的AI平台与AI赋能创新药研发能力,以及康哲药业经验丰富的研发团队和对疾病领域的深度认知,双方共同推进该研发项目的合作开发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-07-13/doc-inihrnpk9058117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BBP","SG9999015945.SGD","IE00BVYPNP33.GBP","VTHR","CHAT","IE00BYV24P56.USD","IE00BVYPNQ40.USD","SBIO","IE00BMCWC346.EUR","GSKH","LU2488822045.USD","00867","IE00BGHQDM52.EUR","QTOC","SG9999015952.SGD","WRND","SG9999015986.USD","ARTY","GDOC","SG9999015978.USD","LFSC","IBB","BK1191","AIPO","SG9999004220.SGD","BK1593","BK4585","PBE","BK4588","AGIX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/BBP\",params:#limit:6,delay:false,,,undefined,":[]}}